Enumeral

Enumeral is a biotechnology company focused on the discovery and development of novel antibody therapeutics. The company utilizes a proprietary platform technology to identify and characterize immune modulators, which are critical in the treatment of cancer and other diseases.

History

Enumeral was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company was established by a group of scientists and entrepreneurs with expertise in immunology, oncology, and antibody discovery.

Technology

Enumeral's platform technology is based on single-cell analysis, which allows for the detailed examination of individual immune cells. This technology enables the identification of unique antibodies that can modulate the immune system, providing potential therapeutic benefits for various diseases.

Single-Cell Analysis

The single-cell analysis technology employed by Enumeral involves isolating individual immune cells and analyzing their responses to different stimuli. This approach provides a high-resolution view of the immune system, allowing for the discovery of novel targets and the development of more effective therapies.

Pipeline

Enumeral's pipeline includes several antibody candidates in various stages of development. These candidates are designed to target specific immune checkpoints and modulate the immune response to treat cancer and other diseases.

Lead Candidates

• ENUM-001: An antibody targeting PD-1, a checkpoint protein on immune cells that, when inhibited, can enhance the body's immune response against cancer cells.
• ENUM-002: An antibody targeting CTLA-4, another checkpoint protein that plays a critical role in regulating immune responses.

Collaborations

Enumeral has established collaborations with various academic institutions and pharmaceutical companies to advance its research and development efforts. These partnerships are aimed at leveraging complementary expertise and resources to accelerate the discovery and development of new therapies.

See Also

• Biotechnology
• Immunotherapy
• Antibody
• Cancer treatment
• Immune system